Videos

Is it still safe to take your child to get a vaccine during the pandemic? According to experts, there are safety measures in place for this critically important task.

Dr. Debra Goff describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

A pediatric cardiologist discusses the specifics of a case study, the importance of adaptability, and how her healthcare system has developed treatment protocols in these cases.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

A health data analytics expert describes how repeat or low-value studies can arise amid the rush to publish pandemic research.

MediFind's Patrick Howie examines the consolidation of resources during pandemics amid concerns that funding will not return to other areas of health research.

What we've seen non-immunized communities do for previously eradicated outbreaks.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.

University of Maryland professor of medical technology answers where limited testing resources ought to be directed given pandemic supply issues.

University of Maryland professor of medical technology explains the ways speed and accuracy are weighed when testing is deployed to detect COVID-19.

A discussion with an Ohio State investigator on early CMR findings among young athletes.

Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.

Robert H. Christenson, PhD, outlines the ways SARS-CoV-2 transmission is prevented during testing, how testing materials are acquired, and more.

A clinical-stage immunology company has an investigational therapy looking to target the tumor necrosis factor cytokine.

An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.

At a time when schools and college campuses have reopened, an expert discusses adolescents' trends in spreading COVID-19 more easily, and the lack of testing available to them.

How children and adolescents contract, spread, and suffer through the virus differently than other age groups.

Rinki Varindani Desai shares some of the challenges COVID-19 patients with lung injury have faced with Medicare after leaving the hospital.

Dysphagia specialist Rinki Varindani Desai shares her perspective on how COVID-19 has impacted her work and patients.

A team at UCSF has created a model which estimates how many pediatric cases are going unnoticed in any US county at any time.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at USP, discusses the recent report of SARS-CoV-2 reinfection.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of convalescent plasma treatment for COVID-19.

Bhopal’s recent article, COVID-19 Zugzwang, was published in Public Health in Practice.

John F. Kokai-Kun, PhD, explains the supply chain and logistical issues limiting the scale of monoclonal antibody treatment.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of monoclonal antibody treatment.

Martin Kulldorff, PhD, explains that masks can't replace social distancing for those at highest risk for severe COVID-19.

Brad Spellberg, MD, explains how real progress can be made to a debted system with worsened rates of user health.

Martin Kulldorff, PhD, answers whether an age based coronavirus strategy would worsen the pandemic's impact on workers and minority racial groups.